Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax on Wednesday said that the postmarketing commitment study is anticipated to occur during 2025 and 2026 and cost ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and ...

Novavax shares shot higher after the biotechnology company's second-quarter profit and revenue beat analyst expectations. Shares were up 15% at $7.73 on Wednesday. The stock is up 33% over the past ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

The stock's rise snapped a seven-day losing streak.

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of 62 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...